“But having said that, we continue to make investments in our business such that we're more productive, top to bottom, therefore, expanding our operating margin profile of the company.”

In context

“as a franchise that's going to be generating healthy growth? Or should we think about growth slowing significantly going forward? Albert Bourla: [indiscernible] you start. Dave Denton: So first, obviously, mid- to high 30s is very much within the realm of our business model. We're very focused against that. We continue to march and make progress against that over time. So we don't have a specific date for at this point in time. But as we continue to progress, both this year and we give guidance for next year, I'm sure you should see us completely progress on that front. Albert Bourla: And I think COMIRNATY was also a little bit the question. Dave Denton: Yes. Well, I think COMIRNATY obviously, is a down draft to that. So obviously, adjusted for the size of that business will be important. But having said that, we continue to make investments in our business such that we're more productive, top to bottom, therefore, expanding our operating margin profile of the company. Albert Bourla: And we don't want to speak for specific products, the markets, right, because it's a little bit misleading. It depends on multiple things. We did it because of the extraordinary circumstances in '22. But in general, you all know that from 2 products, PAXLOVID is very, very high margin and COMIRNATY is on the low. [indiscernible], why don't we start international this time and then we end up with a mirror on [indiscernible] the redesign. Chris Schott: Okay. So on the international, we had a very strong year, and we continue to grow very strongly this quarter at 31%. Actually, our total patients on [indiscernible] have increased by 14% in the third quarter versus the second quarter. So this is a straight [indiscernible] that we are growing, and we continue to add new patients”